Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

NCT02302339 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT02302339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02302339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Lead sponsor
Celldex Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2014
Completion date
October 3, 2018
Enrollment
132 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma